Dow Up0.19% Nasdaq Up0.56%

iBio, Inc. (IBIO)

-NYSE MKT
1.09 Down 0.06(5.22%) 4:00PM EST
|After Hours : 1.08 Down 0.01 (0.92%) 7:59PM EST
ProfileGet Profile for:
iBio, Inc.
9 Innovation Way
Suite 100
Newark, DE 19711
United States - Map
Phone: 302-355-0650
Website: http://www.ibioinc.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:7

Business Summary 

iBio, Inc., a biotechnology company, focuses on the commercialization of its proprietary plant-based protein expression technologies in the United States and internationally. Its proprietary technologies include iBioLaunch, a transformative platform technology for the development and production of therapeutic proteins and vaccines; and iBioModulator, a technology platform that enhances the potency and duration of the effect of prophylactic and therapeutic vaccines. The company’s product candidates comprise IBIO-CFB03, a product for treatment of idiopathic pulmonary fibrosis; C1 Esterase Inhibitor, a plasma-derived protein; Alpha-Galactosidase, an enzyme replacement protein; and Palivizumab, a monoclonal antibody for the therapeutic protein market. Its vaccine products include H1N1 Influenza and H5N1 Influenza products that have completed Phase I human clinical trials, as well as yellow fever vaccine; malaria and hookworm parasitic pathogen vaccines; and human papillomavirus therapeutic vaccine. The company’s product candidates also comprise Anthrax/Plague bacterial disease vaccine; and Anthrax, a monoclonal antibody for the biodefense market. It has strategic alliances and collaborations with various companies, such as Fraunhofer Center for Molecular Biology, GE Healthcare, FioCruz, and Caliber Biotherapeutics LLC. The company is headquartered in Newark, Delaware.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on iBio, Inc.

Key Executives 
 PayExercised
Mr. Robert B. Kay , 74
Exec. Chairman and Chief Exec. Officer
300.00K0.00
Mr. Robert L. Erwin , 61
Pres
230.00K0.00
Mr. Mark Giannone , 57
Chief Financial Officer
22.00K0.00
Mr. Terence E. Ryan Ph.D., 59
Chief Scientific Officer
200.00K0.00
Mr. Douglas Hicks ,
VP of Bus. Devel.
N/AN/A
Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders